Overview

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.
Phase:
PHASE4
Details
Lead Sponsor:
Fundación para la Investigación del Hospital Clínico de Valencia
Treatments:
dapagliflozin